Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI Tool Detects Early Signs of Blood Mutations Linked to Cancer and Heart Disease

By LabMedica International staff writers
Posted on 27 Aug 2025

Deep inside the body, clusters of mutated blood cells can slowly form without symptoms, affecting about one in five older adults. More...

This condition, known as clonal hematopoiesis of indeterminate potential (CHIP), increases the likelihood of leukemia more than tenfold and raises the risk of heart disease up to fourfold. Because it often goes undetected for years, finding CHIP earlier could allow for proactive monitoring or preventive care to reduce risk. Now, an artificial intelligence (AI) tool can find early signs of blood mutations linked to cancer and heart disease.

The AI tool called UNISOM—short for UNIfied SOmatic calling and Machine learning—has been developed by researchers at Mayo Clinic (Rochester, MN, USA) to identify CHIP-related mutations in standard genetic datasets. Unlike earlier methods that required advanced sequencing, this innovation allows clinicians and scientists to uncover subtle DNA changes using existing data, broadening research and potential clinical use.

UNISOM was evaluated in a study published in Genomics, Proteomics & Bioinformatics. The tool successfully detected nearly 80% of CHIP mutations using whole-exome sequencing, which focuses on protein-coding DNA. It also identified mutations present in fewer than 5% of blood cells when tested on whole-genome sequencing data from the Mayo Clinic Biobank, outperforming conventional techniques that often miss such small but significant changes.

By detecting CHIP at its earliest molecular stages, the approach offers a powerful new way to study disease progression and guide patient care. The researchers emphasized that integrating this tool into larger and more diverse datasets could strengthen predictions, enabling earlier detection of high-risk individuals and more precise treatment decisions in the clinic.

"We're engineering a path from genomic discovery to clinical decision-making," said Shulan Tian, Ph.D., the co-senior author and a bioinformatician at Mayo Clinic. "It's rewarding to help bring these discoveries closer to clinical care, where they can inform decisions and support more precise treatment."


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Graphical Abstract: Changes in circulating tumor DNA during Ra-223 treatment reflect disease course in patients with bone-metastatic castration-resistant prostate cancer. (Image created by Masaki Shiota et al., Kyushu University, Fukuoka, Japan)

Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer

Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image Credit: Adobe Stock

New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients

Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.